Predictive and Presymptomatic Testing Market
Genetic testing and screening is the next big thing in the area of molecular diagnostics. Advances in accuracy and steady market growth in genetic testing are opening a number of exciting new doors when it comes to understanding, predicting and eventually treating disease. Today, there are over 2000 clinical tests available to test various monogenetic diseases or acquired chromosomal disorders. The genetic testing market can be fragmented to three broad segments - diagnostic testing, relationship testing and predictive testing.
Of this Predictive testing is acquiring great interest as screening technique for individuals. Predictive and presymptomatic testing is utilized for the detection of gene mutations that are related to disorders appearing after birth, frequently in later stages of life. Such tests can be of assistance to individuals having a family member with a genetic disorder, though they are free of any features themselves of the disorder while testing. Predictive testing can aid in the identification of mutations that can increase an individuals possibilities of developing disorders as in the case of specific cancers.
Globally, the market for predictive & presymptomatic testing is projected to reach US$5.7 billion by 2020 and North America is set to be the highest grossing market closely followed by Europe.
2. Global Predictive and Presymptomatic Testing Market
3. Difference from conventional medical testing
3.1 Individual versus family
4. Commonly Tested Conditions
4.1 Multiple endocrine neoplasia type 2
4.3 Colorectal cancer
4.4 Breast and ovarian cancer
4.5 Alzheimer's disease
5 .Factors affecting utility
6. Possible Benefits of Predictive testing